TrialPath
Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034 · GlaxoSmithKline
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
About this study
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Eligibility criteria
Inclusion criteria: Participants are eligible to be included in the study only if all of the following criteria apply: All cohorts * Is at least 18 years of or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent form (ICF). CRC Cohort * Has histologically confirmed unresectable, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification). PDAC Cohort * Has histologically or cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas (histology defined by WHO classification). All Cohorts * Is willing to use adequate contraception. * Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Has an ECOG performance status of 0 or 1. * Has adequate organ function. Exclusion criteria: Participants are excluded from the study if any of the following criteria apply: * Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \[e.g., breast, cervix, bladder\] that have been resected with no evidence of disease. * Has had any major surgery within 28 days prior to randomization or first dose of study intervention, depending on sub-cohort/cohort assignment * Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. * Has severe, uncontrolled or active cardiovascular disorders. * Has serious or poorly controlled hypertension. * Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose. * Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed. * Has evidence of current ILD/non-infectious pneumonitis or a prior history of ILD/non-infectious pneumonitis requiring high-dose glucocorticoids Or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging. * Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy. * Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload. * Is pregnant or breastfeeding.
Study design
Enrollment target: 346 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-06-11
Estimated completion: 2029-01-09
Last updated: 2026-10-19
Interventions
Biological: Risvutatug Rezetecan
Primary outcomes
  • • Confirmed Objective Response Rate (ORR) (Up to approximately 22 months)
Sponsor
GlaxoSmithKline · industry
Contacts & investigators
ContactUS GSK Clinical Trials Call Center · contact · GSKClinicalSupportHD@gsk.com · 877-379-3718
ContactEU GSK Clinical Trials Call Center · contact · GSKClinicalSupportHD@gsk.com · +44 (0) 20 89904466
All locations (85)
GSK Investigational SiteRecruiting
Los Alamitos, California, United States
GSK Investigational SiteRecruiting
Los Angeles, California, United States
GSK Investigational SiteRecruiting
Santa Monica, California, United States
GSK Investigational SiteRecruiting
Whittier, California, United States
GSK Investigational SiteRecruiting
Aurora, Colorado, United States
GSK Investigational SiteRecruiting
New York, New York, United States
GSK Investigational SiteRecruiting
New York, New York, United States
GSK Investigational SiteRecruiting
Durham, North Carolina, United States
GSK Investigational SiteRecruiting
Houston, Texas, United States
GSK Investigational SiteRecruiting
San Antonio, Texas, United States
GSK Investigational SiteRecruiting
Wenatchee, Washington, United States
GSK Investigational SiteRecruiting
Madison, Wisconsin, United States
GSK Investigational SiteRecruiting
Heidelberg, Victoria, Australia
GSK Investigational SiteRecruiting
Melbourne, Victoria, Australia
GSK Investigational SiteRecruiting
Bonheiden, Belgium
GSK Investigational SiteRecruiting
Brussels, Belgium
GSK Investigational SiteRecruiting
Leuven, Belgium
GSK Investigational SiteRecruiting
Roeselare, Belgium
GSK Investigational SiteRecruiting
Porto Alegre, Brazil
GSK Investigational SiteRecruiting
São Paulo, Brazil
GSK Investigational SiteRecruiting
Teresina, Brazil
GSK Investigational SiteRecruiting
Calgary, Alberta, Canada
GSK Investigational SiteRecruiting
Toronto, Ontario, Canada
GSK Investigational SiteRecruiting
Montreal, Quebec, Canada
GSK Investigational SiteRecruiting
Sherbrooke, Quebec, Canada
GSK Investigational SiteRecruiting
Kuopio, Northern Savonia, Finland
GSK Investigational SiteRecruiting
Helsinki, Finland
GSK Investigational SiteRecruiting
Helsinki, Finland
GSK Investigational SiteRecruiting
Tampere, Finland
GSK Investigational SiteRecruiting
Dijon, France
GSK Investigational SiteRecruiting
Marseille, France
GSK Investigational SiteRecruiting
Paris, France
GSK Investigational SiteRecruiting
Paris, France
GSK Investigational SiteRecruiting
Paris, France
GSK Investigational SiteRecruiting
Poitiers, France
GSK Investigational SiteRecruiting
Rennes, France
GSK Investigational SiteRecruiting
Villejuif, France
GSK Investigational SiteRecruiting
Frankfurt am Main, Hesse, Germany
GSK Investigational SiteRecruiting
Bochum, Germany
GSK Investigational SiteRecruiting
Düsseldorf, Germany
GSK Investigational SiteRecruiting
Lübeck, Germany
GSK Investigational SiteRecruiting
München, Germany
GSK Investigational SiteRecruiting
Roma, RM, Italy
GSK Investigational SiteRecruiting
Milan, Italy
GSK Investigational SiteRecruiting
Milan, Italy
GSK Investigational SiteRecruiting
Pisa, Italy
GSK Investigational SiteRecruiting
Aichi, Japan
GSK Investigational SiteRecruiting
Chiba, Japan
GSK Investigational SiteRecruiting
Hokkaido, Japan
GSK Investigational SiteRecruiting
Osaka, Japan
GSK Investigational SiteRecruiting
Tokyo, Japan
GSK Investigational SiteRecruiting
Tokyo, Japan
GSK Investigational SiteRecruiting
Tuxtla Gutiérrez, Chiapas, Mexico
GSK Investigational SiteRecruiting
Cuernavaca, Morelos, Mexico
GSK Investigational SiteRecruiting
San Pedro Garza García, Nuevo León, Mexico
GSK Investigational SiteRecruiting
Mexico City, Mexico
GSK Investigational SiteRecruiting
Mexico City, Mexico
GSK Investigational SiteRecruiting
Amsterdam, Netherlands
GSK Investigational SiteRecruiting
Maastricht, Netherlands
GSK Investigational SiteRecruiting
Rotterdam, Netherlands
GSK Investigational SiteRecruiting
Utrecht, Netherlands
GSK Investigational SiteRecruiting
Lørenskog, Akershus, Norway
GSK Investigational SiteRecruiting
Oslo, Norway
GSK Investigational SiteRecruiting
Stavanger, Norway
GSK Investigational SiteRecruiting
La Villa de Los Santos, Los Santos Province, Panama
GSK Investigational SiteRecruiting
Punta Pacifica Panama City Panama, Panama
GSK Investigational SiteRecruiting
Brzozów, Poland
GSK Investigational SiteRecruiting
Koszalin, Poland
GSK Investigational SiteRecruiting
Warsaw, Poland
GSK Investigational SiteRecruiting
Seoul, Seoul Teugbyeolsi, South Korea
GSK Investigational SiteRecruiting
Seoul, South Korea
GSK Investigational SiteRecruiting
Seoul, South Korea
GSK Investigational SiteRecruiting
Barcelona, Spain
GSK Investigational SiteRecruiting
Barcelona, Spain
GSK Investigational SiteRecruiting
Madrid, Spain
GSK Investigational SiteRecruiting
Madrid, Spain
GSK Investigational SiteRecruiting
Madrid, Spain
GSK Investigational SiteRecruiting
Pamplona, Spain
GSK Investigational SiteRecruiting
Santander, Spain
GSK Investigational SiteRecruiting
Zaragoza, Spain
GSK Investigational SiteRecruiting
Gothenburg, Sweden
GSK Investigational SiteRecruiting
Lund, Sweden
GSK Investigational SiteRecruiting
Stockholm, Sweden
GSK Investigational SiteRecruiting
Uppsala, Sweden
GSK Investigational SiteRecruiting
Manchester, United Kingdom
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) · TrialPath